Role of mucosal immunity and epithelial–vascular barrier in modulating gut homeostasis

por Di Sabatino, Antonio, Santacroce, Giovanni, Rossi, Carlo Maria, Broglio, Giacomo, Lenti, Marco Vincenzo
Publicado 2023

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

por Burdge, Gemma, Hardman, Alice, Carbery, Isabel, Broglio, Giacomo, Greer, Dan, Selinger, Christian P.
Publicado 2022

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

por Carbery, Isabel, Burdge, Gemma, Clark, Tanya, Broglio, Giacomo, Greer, Dan, Alakkari, Alaa, Selinger, Christian Philipp
Publicado 2023

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients

por Gebeyehu, Gerum Gashaw, Fiske, Joseph, Liu, Eleanor, Limdi, Jimmy K., Broglio, Giacomo, Selinger, Christian, Razsanskaite, Violeta, Smith, Philip J., Flanagan, Paul K., Subramanian, Sreedhar
Publicado 2022